These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2209342)

  • 21. [Circadian profiles of lactic and pyruvic acid in diabetic patients treated with biguanides and sulfonylureas].
    Cheli V; Buzzo P; Melga P; Accoto S; Prando R
    Clin Ter; 1986 Aug; 118(4):269-75. PubMed ID: 3757467
    [No Abstract]   [Full Text] [Related]  

  • 22. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.
    Fisman EZ; Tenenbaum A; Benderly M; Goldbourt U; Behar S; Motro M
    Cardiology; 1999; 91(3):195-202. PubMed ID: 10516414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R
    J Am Board Fam Pract; 1997; 10(3):213-21. PubMed ID: 9159660
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?
    Groop L; Widén E
    Diabete Metab; 1991 May; 17(1 Pt 2):218-23. PubMed ID: 1936480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
    Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
    Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihyperglycaemic agents. Drug interactions of clinical importance.
    Scheen AJ; Lefèbvre PJ
    Drug Saf; 1995 Jan; 12(1):32-45. PubMed ID: 7741982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral treatment in diabetes.
    Stowers JM
    Clin Endocrinol Metab; 1972 Nov; 1(3):721-50. PubMed ID: 4204135
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological treatment of type 2 diabetes.
    Hermans MP; Buysschaert M
    Acta Clin Belg; 2004; 59(2):59-66. PubMed ID: 15224468
    [No Abstract]   [Full Text] [Related]  

  • 29. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
    Jennings PE
    Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biguanide related lactic acidosis: incidence and risk factors.
    Aguilar C; Reza A; García JE; Rull JA
    Arch Med Res; 1992; 23(1):19-24. PubMed ID: 1308787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of type 2 diabetes mellitus with special reference to metformin therapy.
    Campbell IW
    Diabete Metab; 1991 May; 17(1 Pt 2):191-6. PubMed ID: 1936475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effects of some oral hypoglycemia drugs on blood levels of lactic and pyruvic acid in diabetes mellitus].
    Sgambato S; Bisesti V; Giugliano D; Passariello N; Saccomanno F
    Clin Ter; 1980 Apr; 93(2):183-92. PubMed ID: 7449337
    [No Abstract]   [Full Text] [Related]  

  • 35. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Biguanides in the treatment of obesity].
    Giulietti M
    Clin Ter; 1978 Jan; 84(1):99-100. PubMed ID: 415837
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination insulin-sulfonylurea therapy.
    Lebovitz HE; Pasmantier R
    Diabetes Care; 1990 Jun; 13(6):667-75. PubMed ID: 2192850
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin.
    Evans JM; Ogston SA; Emslie-Smith A; Morris AD
    Diabetologia; 2006 May; 49(5):930-6. PubMed ID: 16525843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical use of oral sulfonylureas in the management of non-insulin dependent diabetes mellitus (NIDDM).
    Ponte CD
    W V Med J; 1990 Oct; 86(10):455-8. PubMed ID: 2238629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.